Clinical Trials

Real-Time Clinical Trials A New Regulatory Model

Q: What are FDA's RTCT and how do they differ from traditional clinical trial monitoring?

FDA's RTCT allow agency reviewers to access pre-agreed safety and efficacy signals as a trial is actively running, eliminating the traditional wait for sponsors to collect, clean, and submit data through the conventional review cycle. Unlike standard clinical data management workflows, RTCT enables continuous data transmission directly to FDA, as demonstrated by two oncology proof-of-concept studies already live in 2026.

Q: What are the biggest unresolved challenges in FDA's real-time clinical trial initiative?

Key open questions in RTCT include how continuous data review affects blinding and statistical multiplicity control in adaptive trial design, whether FDA has sufficient reviewer capacity to act on streaming data rather than finished study reports, and how accountability is assigned when data flows around a sponsor rather than through it. These regulatory strategy and clinical trial design questions remain critical for sponsors evaluating participation.

Q: How could real-time clinical trial management systems impact drug development timelines and the FDA drug approval process?

RTCT has the potential to compress drug development timelines by giving FDA reviewers earlier visibility into safety and efficacy signals, potentially enabling faster go/no-go decisions and reducing post-submission review lag. However, experts caution that if the true bottleneck in the FDA drug approval process is interpreting ambiguous data rather than transmitting it, the timeline gains may be more limited than anticipated.

Q: What should pharmaceutical sponsors do now to prepare for FDA's real-time clinical trial requirements?

Sponsors should assess their current clinical data management infrastructure, real-time clinical trial management systems, and data safety monitoring board protocols to identify gaps before engaging with FDA's RTCT pilot. Given the number of unresolved regulatory and operational questions, Axtria recommends a measured, well-informed approach, calibrating investment to the initiative's current stage rather than overhauling R&D operations preemptively.

Download White Paper

In April 2026, the FDA announced concrete steps toward “real-time clinical trials” (RTCT) giving reviewers access to pre-agreed safety and efficacy signals while a trial is still running, ahead of the traditional cycle of collecting, cleaning, and submitting data. Two oncology proof-of-concept studies are already transmitting data, with a broader pilot expected to select its first participants later this year. It's a well-resourced shift in regulatory posture, and, by the FDA's own account, one with a long list of open questions.

What Actually Changes

Traditionally, sponsors clean and analyze data before it reaches the FDA at defined milestones. Under RTCT, pre-agreed signals are transmitted through a shared platform as the trial runs. What is not shared under RTCT is full electronic health record access and open-ended visibility into raw data. As of mid-2026 the initiative rests on two oncology studies plus a request for information. RTCT is not yet a finalized framework, and it isn't established how, or whether, it extends beyond early-phase oncology.

Why This Could Matter

Faster safety response: Earlier visibility into adverse signals for faster participant protection.
Shorter development timelines: Compressing the pause between phases, especially in high-unmet-need indications.
More informed early decisions: Continuous data could sharpen dose-selection and futility calls earlier.
A push toward infrastructure modernization: The data-readiness bar RTCT implies has value for pharmacovigilance and Data and Safety Monitoring Board (DSMB) reporting well beyond compliance.

What Remains Unresolved

Data quality, privacy, and AI reliability: Raw, in-flight data isn't equivalent to cleaned, sponsor-reviewed data. The FDA's AI-enabled analytics still need a validation standard.
Statistical and blinding risk: Rolling review instead of pre-specified analysis points raises multiplicity concerns. It's unclear how the FDA discusses a signal without functionally unblinding a study.
Undefined scope and accountability: Success criteria, validation standards, and a scaling timeline remain unpublished. It's unclear who's responsible when data reaches the FDA without passing through the sponsor.
Reviewer and infrastructure capacity: Whether reviewers have the bandwidth for streaming data, and whether today's fragmented data systems can interoperate in real time, are both untested.

Key Factors to Watch Out For

The FDA's complete pilot participant selection
How rolling review reconciles with statistical analysis plans and DSMB oversight
Whether the initiative expands beyond oncology, and results from TRAVERSE and STREAM-SCLC

FAQs

What are FDA's RTCT and how do they differ from traditional clinical trial monitoring?

What are the biggest unresolved challenges in FDA's real-time clinical trial initiative?

How could real-time clinical trial management systems impact drug development timelines and the FDA drug approval process?

What should pharmaceutical sponsors do now to prepare for FDA's real-time clinical trial requirements?

Clinical Solutions Clinical Trials Drug Development RTCT RWE & HEOR

Redefining Commercial Insights with Data Products

Download White Paper

Complete the brief form to download the white paper

Recommended insights

White Paper

Real-Time Clinical Trials A New Regulatory Model

Learn more

Reports

Tokenization in Clinical Development

Learn more

White Paper

The Rise of Multi-Indication Therapies: Limitations of Existing Frameworks and Pathways for Future Innovation

Learn more